All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @jacoboestreichercoaching on TikTok · 104s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @jacoboestreichercoaching's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00MK-677 is fucking stupid.
  2. 0:04Do not take it.
  3. 0:06Most of the people who ask about MK-677 think it's gonna be this magic bill that's gonna suddenly make them jacked.
  4. 0:12But first of all, that's just not true.
  5. 0:14Second of all, they're actually our side effects.
  6. 0:16Third of all, you haven't even been lifting long enough.
  7. 0:18Use some fucking delayed gratification before putting your health at risk.
  8. 0:22You don't have any habits built up to even get the most out of it in the first place.
  9. 0:26And you're trying to go...
  10. 0:28...like, take a drug?
  11. 0:29So this is really the main issue I have with MK is that...
  12. 0:33...it could literally fuck up your insulin sensitivity forever.
  13. 0:37And potentially give you type 2 diabetes if you are on it for long enough.
  14. 0:41Most of you guys are like 16 years old who were asking me about this shit, never trained for more than a year, never died it for more than a year.
  15. 0:48Don't even get 8 hours of sleep and I don't even have a...
  16. 0:51...hate their protein consistently every day.
  17. 0:53And they want to take performance enhancing drugs.
  18. 0:56I encourage you to look at the side effects of it.
  19. 0:59They didn't pass clinical trials with MK-677.
  20. 1:02There are no current long-term studies on MK-677.
  21. 1:06So especially if you're running it for a long period of time,
  22. 1:09you could have side effects that are not seen because it has not been tested.
  23. 1:13So please, let's not take drugs because you are too unsatisfied with your physique,
  24. 1:18because you haven't even trained long enough and you have literally no delayed gratification.
  25. 1:22Try training for the next four years consistently tracking all your calories,
  26. 1:26sleeping 8 hours a night, prioritizing high protein, whole foods diet,
  27. 1:29having simple fast digesting carbs from your diet and training really hard
  28. 1:33on a split you really enjoy with exercises you like.
  29. 1:36Do that for four to five years consistently and then come back to me
  30. 1:40if you want to compete and take bodybuilding seriously about PEDs.

@jacoboestreichercoaching's peptide therapy claims checked

Jacob Oestreicher

TikTok creator

90.1K viewsWatch on TikTok

Quick answer

MK-677 (ibutamoren) is an unapproved ghrelin mimetic that stimulates growth hormone and IGF-1 release. Controlled studies consistently show it impairs insulin sensitivity and raises fasting glucose, effects that are relevant regardless of age or training status. The creator's specific concern about insulin resistance and diabetes risk in unsupervised, long-term use reflects documented pharmacological mechanisms, not speculation.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @jacoboestreichercoaching's peptide therapy claims checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@jacoboestreichercoaching's peptide therapy claims checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@jacoboestreichercoaching's peptide therapy claims checked" from Jacob Oestreicher. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: MK-677 (ibutamoren) is an unapproved ghrelin mimetic that stimulates growth hormone and IGF-1 release.

The reason this review is not generic is the source wording and the canonical claim label "peptides greenscreensticker." In this clip, the useful excerpt is: "MK-677 is fucking stupid." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

MK-677 has never received FDA approval.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

MK-677 (ibutamoren) is an unapproved ghrelin mimetic that stimulates growth hormone and IGF-1 release.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • MK-677 (ibutamoren) is an unapproved ghrelin mimetic that stimulates growth hormone and IGF-1 release. Controlled studies consistently show it impairs insulin sensitivity and raises fasting glucose, effects that are relevant regardless of age or training status. The creator's specific concern about insulin resistance and diabetes risk in unsupervised, long-term use reflects documented pharmacological mechanisms, not speculation.
  • Svensson et al. (1998) found MK-677 significantly increased fasting blood glucose and reduced insulin sensitivity in healthy adults after just two weeks of use.
  • MK-677 has never received FDA approval. It is not classified as a SARM, but is frequently and incorrectly grouped with them in online fitness communities.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Svensson et al. (1998) found MK-677 significantly increased fasting blood glucose and reduced insulin sensitivity in healthy adults after just two weeks of use.
  • MK-677 has never received FDA approval. It is not classified as a SARM, but is frequently and incorrectly grouped with them in online fitness communities.
  • A 12-month controlled trial by Murphy et al. (1998) found insulin resistance persisted throughout the entire treatment period in elderly subjects, not just at the start.
  • The creator's 'failed clinical trials' framing is imprecise: multiple trials were conducted, some showed efficacy signals, and development was halted for a mix of safety concerns and commercial reasons.
  • No long-term safety data exists for MK-677 use in healthy young adults pursuing body composition goals. Every major trial enrolled older adults or clinical populations.
  • Documented side effects beyond insulin resistance include edema, increased appetite, fatigue, and elevated cortisol in some study populations (Chapman et al., 1996).
  • The creator's core harm-reduction message, that beginners without consistent training and nutrition habits have little to gain and measurable metabolic risks to take on, is supported by the available evidence.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @jacoboestreichercoaching actually say?

The creator's core argument is that MK-677 is a bad idea, especially for young, undertrained people. His specific claims: it "could literally fuck up your insulin sensitivity forever," it could "potentially give you type 2 diabetes," it "didn't pass clinical trials," and there are "no current long-term studies" on it. He directed most of his frustration at teenagers who haven't trained seriously yet and want a shortcut. That's the actual argument here, not a blanket anti-peptide stance.

He also recommended a fairly specific alternative: four to five years of consistent training, calorie tracking, eight hours of sleep, and a high-protein whole-foods diet before even considering performance-enhancing drugs. The framing is harm reduction aimed at beginners, not a clinical analysis of MK-677's risk profile.

Does the science back this up?

On insulin sensitivity, the creator is largely correct, and this is well-documented. MK-677 is a ghrelin mimetic and growth hormone secretagogue. Elevated growth hormone and IGF-1 are known to antagonize insulin signaling. Multiple controlled studies have confirmed this signal.

Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) showed that MK-677 administration significantly increased fasting blood glucose and reduced insulin sensitivity in healthy adults after just two weeks. A longer 12-month trial by Murphy et al. (1998, same journal) in elderly subjects found persistent insulin resistance throughout the treatment period. These aren't fringe findings. The insulin effect is one of the more replicated observations in the MK-677 literature.

The "failed clinical trials" claim is trickier. MK-677 (ibutamoren) has been studied in clinical trials for muscle wasting, growth hormone deficiency, and hip fracture recovery. It has not received FDA approval, but "failed clinical trials" isn't quite the same as "was never tested." Some trials were discontinued for metabolic safety reasons. The distinction matters.

What did they get wrong (or right)?

The insulin sensitivity and diabetes risk claim is credible and backed by the literature. Credit where it's due.

But "they didn't pass clinical trials" is imprecise in a way that matters. Merck and Aeterna Zentaris conducted multiple Phase 2 and Phase 3 trials with ibutamoren. A notable example is the Phase 3 trial in hip fracture patients (Adunsky et al., 2011, Archives of Gerontology and Geriatrics), which showed some efficacy signals but raised safety concerns including edema and congestive heart failure in older subjects. The compound hasn't been approved, but saying it "didn't pass" implies a single clean rejection. The reality is messier: some trials showed benefit, some raised safety flags, and development was halted for commercial and safety reasons combined.

The "no current long-term studies" claim is also overstated. There are studies up to 24 months. What he probably means is there are no long-term safety studies in healthy young adults using it for bodybuilding purposes, which is true and actually the more important point he should have made.

What should you actually know?

MK-677 is not approved by the FDA. It is not a SARM, despite being marketed alongside them. It works by mimicking ghrelin and stimulating pituitary GH release. The metabolic side effects, specifically insulin resistance, water retention, and increased appetite, are not rare or theoretical. They show up consistently in the controlled data.

The population this creator is addressing, young, undertrained individuals hoping for muscle gains, is also the population with the least clinical data. Every trial that exists involved older adults, growth hormone-deficient patients, or people recovering from fractures. Extrapolating to a 16-year-old who trains inconsistently is genuinely unsupported by evidence.

Other documented side effects include edema, fatigue, and increased cortisol in some studies (Chapman et al., 1996, Journal of Clinical Endocrinology and Metabolism). The appetite stimulation is significant enough that it can work against body composition goals unless caloric intake is tightly managed, which, as the creator notes, most beginners are not doing.

If you are considering any growth hormone secretagogue, that conversation belongs with a licensed physician who can order baseline metabolic labs, not a TikTok comment section.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Jacob Oestreicher · TikTok creator

90.1K views on this video

#greenscreensticker

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about svensson et al. (1998) found mk-677 significantly increased fasting blood?

Svensson et al. (1998) found MK-677 significantly increased fasting blood glucose and reduced insulin sensitivity in healthy adults after just two weeks of use.

What does the video say about mk-677 has never received fda approval. it?

MK-677 has never received FDA approval. It is not classified as a SARM, but is frequently and incorrectly grouped with them in online fitness communities.

What does the video say about a 12-month controlled trial by murphy et al. (1998) found?

A 12-month controlled trial by Murphy et al. (1998) found insulin resistance persisted throughout the entire treatment period in elderly subjects, not just at the start.

What does the video say about the creator's 'failed clinical trials' framing?

The creator's 'failed clinical trials' framing is imprecise: multiple trials were conducted, some showed efficacy signals, and development was halted for a mix of safety concerns and commercial reasons.

What does the video say about no long-term safety data exists for mk-677 use in healthy?

No long-term safety data exists for MK-677 use in healthy young adults pursuing body composition goals. Every major trial enrolled older adults or clinical populations.

Documented side effects beyond insulin resistance include edema, increased appetite, fatigue, and elevated cortisol in some study populations (Chapman et al., 1996)?

Documented side effects beyond insulin resistance include edema, increased appetite, fatigue, and elevated cortisol in some study populations (Chapman et al., 1996).

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Jacob Oestreicher, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.